Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIp Group Share News (IPO)

Share Price Information for Ip Group (IPO)

Share Price is delayed by 15 minutes
Get Live Data
64.00    0.00 (0.00%)
Bid:
0.00
Ask:
70.00
Spread: 6.40 (10.063%)
Market Cap: £565.39m
IPO Live PriceLast checked at - London Stock Exchange

Intraday Ip Group Share Chart

IP Group describes first half performance as 'robust'

Wed, 25th Jul 2018 08:28
(Sharecast News) - Intellectual property-based business developer IP Group announced its half-yearly results for the six months ended 30 June on Wednesday, reporting net portfolio gains of £0.7m, down from £28.7m at the same time last year.The FTSE 250 firm said the fair value of its portfolio was £1.16bn at period end, a significant improvement £0.66bn a year ago and £1.13bn at year-end.Total capital provided to portfolio companies and projects in the half was £46.9m, up from £20.1m year-on-year, with "significant" funding rounds completed by Oxford Nanopore Technologies of £100.0m, Crescendo Biologics of $70.0m, Carisma Therapeutics of $53.0m, and Enterprise Therapeutics of £29.0m.Microbiotica entered into multi-year strategic collaboration with Genentech - a member of the Roche Group - in a deal worth up to $534.0m during the period, the board highlighted.It also noted that Ceres Power signed a strategic collaboration with China's Weichai Power, comprising both product development and launch, as well as an equity investment, before announcing an oversubscribed £20.0m fundraising in July.Looking at the books, IP Group's net assets were £1.49bn at period end, compared to £0.97bn a year ago and £1.51bn at the end of the 2017 financial year.Hard net asset value stood at £1.3bn, rising from £0.9bn at the same time in 2017 but down from £1.33bn at year-end.Its return on hard net asset value was a negative £13.1m in the half, compared to positive returns of £21.3m and £64.1m for the 2017 half and full years respectively.Gross cash and deposits as at 30 June stood at £258.5m, down from £263.1m a year ago and £326.3m at the full-year."The underlying performance of the group's portfolio has been robust in the first half with a number of our companies completing both major fundraisings and collaborations," said IP Group chief executive officer Alan Aubrey."Our portfolio is well diversified, both by sector and stage of development, with multiple opportunities to crystallise value and there are a number of inflection points for several of our companies over the next six to twelve months."Aubrey said IP Group remained "financially sound", with a "strong" balance sheet, net assets of £1.5bn and exposure to the UK, US, Australasia, and increasingly Asia."The group remains excited by the opportunities within the portfolio and we look to the second half of the year and beyond with confidence."

Related News

WINNERS & LOSERS: Howden's acquisition; B&M signals recovery on track
3 Jun 2026

WINNERS & LOSERS: Howden's acquisition; B&M signals recovery on track

(Alliance News) - The following are the leading risers and fallers among FTSE 100 and 250 index constituents on Wednesday.

IP Group cheers trial results for Enterprise drug candidate
12 May 2026

IP Group cheers trial results for Enterprise drug candidate

(Alliance News) - IP Group PLC on Monday noted positive test results for a cystic fibrosis treatment developed by one of its portfolio firms.

IN BRIEF: IP Group names Michael Queen as next chair, succeeding Flint
7 May 2026

IN BRIEF: IP Group names Michael Queen as next chair, succeeding Flint

IP Group PLC - London-based investor in "breakthrough" science and technology firms - Appoints Michael Queen as chair designate, and as a non-executi...

Ip Group News

WINNERS & LOSERS: Howden's acquisition; B&M signals recovery on track
3 Jun 2026

WINNERS & LOSERS: Howden's acquisition; B&M signals recovery on track

(Alliance News) - The following are the leading risers and fallers among FTSE 100 and 250 index constituents on Wednesday.

IP Group cheers trial results for Enterprise drug candidate
12 May 2026

IP Group cheers trial results for Enterprise drug candidate

(Alliance News) - IP Group PLC on Monday noted positive test results for a cystic fibrosis treatment developed by one of its portfolio firms.

IN BRIEF: IP Group names Michael Queen as next chair, succeeding Flint
7 May 2026

IN BRIEF: IP Group names Michael Queen as next chair, succeeding Flint

IP Group PLC - London-based investor in "breakthrough" science and technology firms - Appoints Michael Queen as chair designate, and as a non-executi...

LONDON BROKER RATINGS: Jefferies cuts National Grid to 'hold'
18 Mar 2026

LONDON BROKER RATINGS: Jefferies cuts National Grid to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

IP Group asset value grows, remains confident in biotech potential
17 Mar 2026

IP Group asset value grows, remains confident in biotech potential

(Alliance News) - IP Group PLC on Tuesday highlighted a successful acquisition by portfolio holding Pfizer Inc, as the investor in science and technol...

LONDON MARKET OPEN: FTSE 100 outperforms Europe as oil rises
17 Mar 2026

LONDON MARKET OPEN: FTSE 100 outperforms Europe as oil rises

(Alliance News) - Stock prices in London opened mixed on Tuesday, as the FTSE 100 was helped by oil majors to outperform European peers, while Trustpi...

IP Group commits USD35 million to autonomous driving firm Oxa
4 Mar 2026

IP Group commits USD35 million to autonomous driving firm Oxa

(Alliance News) - Shares in IP Group PLC rose on Wednesday, as the firm noted its participation in a USD103 million fundraise by Oxa Autonomy Ltd.

Oxa secures $103m in Series D funding
4 Mar 2026

Oxa secures $103m in Series D funding

(Sharecast News) - Intellectual property investor IP Group revealed on Wednesday that portfolio company Oxa Autonomy has completed its Series D fundin...